This study provides Class III evidence that for IVT-treated patients with AIS, DAPP is not associated with a significantly higher risk of sICH. The study lacked the precision to exclude a potentially meaningful increase in sICH bleeding risk.
Background: MSU’s are capable of ultra-early treatment of acute stroke patients in the field. We tested field use of a high-resolution CT and CT-angiography on our MSU. Methods: We designed and implemented the first of its kind MSU equipped with a 16 slice CT scanner (24-row adaptive detector array, fixed 70 cm gantry, auto-injection system, Somatom Scope, Siemens), led by stroke fellowship trained MDs or ANVP-board certified nurse practitioners without telemedicine support. Head/neck CTA was performed on all suspected stroke patients immediately following noncontrast CT. The MSU is embedded within local Fire/EMS and is activated by 911, or by on-scene medics 14 days/month. Transport and drug re-stock agreements were developed with Comprehensive, Primary, and CSC-Capable (CSC-cap) competing stroke centers. Results: Of 420 activations in the first year, our MSU transported a total 206 patients: 127 (62%) strokes and 79 (38%) stroke mimics. In all 127 acute stroke patients (68±16 years, 58% women, 65% African American, 34% White, 1% Hispanic), median CT/CTA completion time, from start of scan, to images ready for diagnostic viewing, was 3.5 minutes (IQR 3-4). Diagnosis was 15 (12%) hemorrhages, 12 (9%) suspected TIA, 100 (79%) acute ischemic stroke (AIS). AIS median NIHSS was 9, IQR 7-17. IV-tPA treatment rate was 38% with median scene arrival to bolus time of 13 min, IQR 11-16. Large vessel occlusion (LVO) was found in 30% of ischemic strokes. No patients required repeat imaging on arrival due to image quality, and 100% were accurately triaged to CSC, PSC, or CSC-cap hospitals without the need for subsequent transfer. Conclusions: MSUs can effectively operate a high-resolution automated CT similar to in-hospital radiology settings. The addition of head/neck CTA in the field yields a high rate of LVO detection supporting definitive prehospital triage to Comprehensive Stroke Centers.
Patient: Female, 58Final Diagnosis: NMOSymptoms: New-onset right leg weakness and painMedication: —Clinical Procedure: Progressive and recurringSpecialty: NeurologyObjective:Rare diseaseBackground:Neuromyelitis optica (NMO) is a rare demyelinating disease of the central nervous system; NMO predominantly affects the spinal cord and optic nerves. The diagnosis is based on history, clinical presentation, seropositive NMO-IgG antibody, and notably, exclusion of other diseases. Despite the absence of definitive therapeutic strategies for NMO, methylprednisolone pulse therapy and plasma exchange are used for acute phase treatment, while immunosuppressive agent(s) are recommended to prevent relapses and improve prognosis. Here, we report a repeating relapse NMO case due to lack of regular and maintenance therapy.Case Report:A 58-year-old female with chronic NMO presented with a three-day history of new-onset right leg weakness and pain. The patient was diagnosed with NMO three years ago and presented with her fourth attacks. During her initial diagnosis, she was initiated on steroids. One year later, she developed the first relapse and was treated with steroids and rituximab, leading to 1.5-year remission. After the second relapse, steroids and rituximab was still given as maintenance therapy, but was not followed. Thus, the third relapse occurred in five months. During this hospitalization, she received initially high-dose solumedrol (1 g daily for five days) in addition to gabapentin 100 mg (gradually increased to 300 mg) three times a day for muscle spasms. Due to worsening of paresthesia and hemiparesis, it was decided to place her on plasma exchange treatment. After two plasma exchanges, the patient’s condition was improved and she regained strength in her lower extremity. She completed five more cycles of plasma exchange, and was then discharged on steroid therapy (prednisone 20 mg daily for 10 days then taper) as maintenance therapy and with follow-up in neurology clinic.Conclusions:Over the span of three years, the patient has had three relapses since her NMO diagnosis where her symptoms have worsened. Steroid therapy alone seemed not insufficient in managing her more recent relapses. Nonadherence to NMO treatment likely increased her risk for recurrence, thus regular and long-term maintenance therapy is imperative to delay the progression and prevent relapse in NMO.
Background: Lowering of blood pressure (BP) is discouraged in current ASA guidelines for emergency medical service (EMS) personnel. However, ultra-early treatment with IVtPA and BP lowering in ICH are possible on mobile stroke units (MSU). We examined the effectiveness and safety of two antihypertensive agents for MSU treatment. Methods: Consecutive MSU patients were treated with target ICH BP parameters less than 140/90, and IVtPA BP parameters by current guidelines. BP was measured by noninvasive oscillometric cuff, and cycled every 5 minutes per EMS MSU protocol. Available agents were labetalol IV 10-20mg and/or nicardipine double-strength premix infusion started at 5mg/hour and titrated. Preference in usage, and effect were recorded and analyzed for the first year of MSU operation. Results: During 168 service days, 127 acute stroke patients were transported (68±16, range 23-96 years; 58% women; 65% African American, 34% White; 1% Hispanic). Fifteen (12%) had hemorrhage on CT (1 aneurysmal SAH, 1 SDH, 1 subacute AIS with HT-2; 12 HTN ICH [median ICH score 2, IQR 1-3] of which 1 had a positive spot sign on CTA). AIS cases (n=100) had median NIHSS 9 (IQR 7-17); 38% were treated with IVtPA at a median 13 (IQR 11-16) minutes from scene arrival, one of these by IO route, with 1 angioedema and 0 sICH. Labetalol was used for 9 patients, with all but one (89%) requiring the addition of nicardipine infusion. In 24 patients nicardipine was the first agent selected, with 100% achieving target BP control prior to hospital arrival. Conclusions: MSU use of nicardipine double-strength premix infusions provides rapid, reliable, and safe BP control. When time is of the essence, elimination of labetalol, in favor of a dihydropyridine calcium channel blocker infusion may provide the most rapid achievement of prescribed BP parameters.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.